[Special Stock] Samsung Biologics Hits Record High on Surpassing 2 Trillion KRW in H1 Sales

Samsung Biologics hit a 52-week high, driven by strong first-half performance.

As of 9:51 a.m. on the 26th, Samsung Biologics was trading at 915,000 KRW, up 44,000 KRW (5.05%) from the previous close on the KOSPI market. The trading volume was around 130,000 shares, with a trading value of 114.2 billion KRW.

The stock opened at 873,000 KRW and reached an intraday high of 929,000 KRW, setting a new 52-week high. Afterwards, some profit-taking emerged, partially reducing the gains.

On a consolidated basis, Samsung Biologics reported first-half sales of 2.1038 trillion KRW, up 32.56% year-on-year, and operating profit of 655.8 billion KRW, up 47.31%. This is the first time sales have exceeded 2 trillion KRW since the company's founding.

Samsung Biologics stated that the strong performance was due to large-scale orders, increased utilization of Plant 4, and milestone payments received following the approval of biosimilar products by Samsung Bioepis.